Halozyme Therapeutics, Inc. (HALO) Stock Price & Analysis

Halozyme Therapeutics, Inc. (HALO) fell 0.51% to USD 110.19 as of September 8, 2026 at 05:44 UTC, according to Nexqual real-time market data.

HALO last closed at USD 110.76; the session ranged USD 109–111.15 on volume of 1,010,602 shares. Market capitalization is $12.51B, with a 52-week range of USD 61.23–111.15 (NMS). Source: Nexqual, September 8, 2026 at 05:44 UTC.

Key Statistics (as of September 8, 2026 at 05:44 UTC)

Technical Analysis (HALO)

Nexqual's technical model rates HALO "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:44 UTC.

Analyst Ratings (HALO)

Wall Street analysts rate HALO "Buy" based on 9 analysts, with a mean price target of USD 99.56 (range USD 70–115), per Nexqual as of September 8, 2026 at 05:44 UTC.

Earnings (HALO)

Recent Earnings History

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Financials & Fundamentals (HALO)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Financial Health Score (HALO)

Nexqual rates Halozyme Therapeutics, Inc.'s overall financial health "Solid" across five dimensions, as of September 8, 2026 at 05:44 UTC.

Ownership (HALO)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

Leadership (HALO)

Halozyme Therapeutics, Inc. is led by Helen I. Torley M.B. Ch. B., M.R.C.P. (age 62), President, CEO & Director, per Nexqual as of September 8, 2026 at 05:44 UTC.

Major Backers & Investors (HALO)

Notable institutional backers of Halozyme Therapeutics, Inc. include Invesco, Morgan Stanley, Boston Partners, according to Nexqual as of September 8, 2026 at 05:44 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 8, 2026 at 05:44 UTC.

From Halozyme Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-17)

Key Strengths & Strategy (as disclosed to the SEC)

• We will also continue our efforts to enter into new collaborations to derive additional revenue from our proprietary technology.
• In April 2023, Takeda announced the FDA approved the supplemental Biologics License Application to expand the use of HYQVIA to treat Primary Immunodeficiency in children.
• Teva's Epinephrine Injection, utilizing our patented VIBEX ® injection technology, was approved by the FDA as a generic drug product with an AB rating, meaning that it is therapeutically equivalent to the branded products EpiPen ® and EpiPen Jr ® and therefore, subject to state law, substitutable at the pharmacy.
• For our products and product candidates, we verify that they are manufactured in accordance with FDA's current Good Manufacturing Practices for drug products and the FDA's current Quality System Regulations for medical devices and equivalent provisions in the EU and elsewhere, which are required as part of the overall obligations necessary, in the EU for instance, to obtain a CE-mark.

Partnerships

• Device and Other Drug Product Collaborations Teva License, Development and Supply Agreements In July 2006, we entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada.
• In December 2025, we entered into a commercial license and supply agreement with Viatris under which we license and supply an auto-injector product for self-administered SC selatogrel for the treatment of acute myocardial infarction in adult patients. 17 Table of Contents Patents and Intellectual Proprietary Rights Patents and other intellectual proprietary rights are essential to our business.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:44 UTC. This page is informational and not investment advice.